• Nuvation Bio completed a process tech transfer to Thermo Fisher Scientific for U.S.-based final drug product manufacturing of IBTROZI (taletrectinib), its ROS1-positive non-small cell lung cancer therapy.
• Transition was submitted as a supplement to IBTROZI New Drug Application held by Nuvation Bio, with work now complete.
• Shift moves commercial supply closer to US patients, targeting supply continuity for an FDA-approved oncology product.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605131605PR_NEWS_USPR_____NY55390) on May 13, 2026, and is solely responsible for the information contained therein.